Abstract
Overexpression of tumor necrosis factor alpha (TNF-α) has been demonstrated to play a pivotal role in the pathogenesis of both plaque-type psoriasis and psoriatic arthritis. TNF-α blockers, including etanercept, a human protein that acts as a TNF-α soluble receptor, are effective in the treatment of psoriasis. This retrospective study investigated the impact of psoriasis patients' demographic and clinical characteristics on primary inefficacy to etanercept. Our findings suggest that the presence of psoriatic arthritis is a risk factor for primary inefficacy to etanercept in the treatment of psoriasis. However, etanercept efficacy appears to be independent of patient age, gender, or previous biologic treatments.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Drug development research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
